MULTIPLE SCLEROSIS (MS)
Multiple Sclerosis (MS) is the most important inflammatory disease of the central nervous system in the western world (approximately 0,85 million patients in Northern Europe and the USA). It is characterized by highly variable clinical aspects and an unpredictable course. Of the many symptoms encountered in MS, muscle spasticity and spasms occur in up to 75% of patients. The endogenous cannabinoid system appears to be tonically active in the control of spasticity.
Cannabinoids have been proposed as therapeutic options for spasticity in MS because of their ability to reduce the feeling of spasticity. Cannabinoids have been shown to modulate motor cortical excitability probably through presynaptic cannabinoid receptors CB1, that control the release of neurotransmitters from axonal terminals.
Namisol® in MS
Using a pioneering smart design, based on the pharmacokinetic and pharmacodynamic response of the individual patient, an individual dosing regimen will be generated regarding Namisol®. Main objectives of the study are to evaluate the efficacy, safety and tolerability of Namisol® in Multiple Sclerosis (MS) patients suffering from spasticity and pain.
In this clinical study biomarkers are included to evaluate the anti-inflammatory potential and the inhibition of neurodegeneration which might be indicative for the disease-modifying potential of Namisol®.
If you are a patient with Multiple Sclerosis and are interested in participating in this study, please click here.
